Skip to main content

Table 3 Logistic regression analysis between SBP trajectory groups and abnormality for indicators of kidney disease in 2016

From: Unstably controlled systolic blood pressure trajectories are associated with markers for kidney damage in prediabetic population: results from the INDEED cohort study

 Group 1Group 2Group 3Group 4Group 5
N (%)726 (50.3%)323 (22.3%)176 (12.1%)181 (12.5%)45 (2.8%)
eGFR < 60 ml/min/1.73 m2
 Model 10.66 (0.11, 4.01)1.000.92 (0.08, 10.19)2.71 (0.45, 16.34)3.65 (0.32, 41.06)
 Model 20.41 (0.06, 2.51)1.000.41 (0.04, 4.75)1.18 (0.18, 7.71)1.33 (0.11, 16.04)
 Model 30.41 (0.07, 2.54)1.000.42 (0.04, 4.88)1.17 (0.18, 7.66)1.30 (0.11, 15.87)
Model 40.32 (0.04, 2.30)1.000.23 (0.02, 3.07)0.78 (0.10, 5.99)0.86 (0.06, 11.36)
 Model 50.32 (0.04, 2.35)1.000.18 (0.01, 2.71)0.61 (0.07, 5.74)0.73 (0.05, 10.24)
3 mg/mmol ≤ uACR ≤ 30 mg/mmol
 Model 10.99 (0.64, 1.52)1.001.67 (1.02, 1.24)*2.32 (1.52, 3.56)*1.18 (0.41, 3.41)
 Model 20.97 (0.63, 1.51)1.001.62 (0.97, 2.69)2.26 (1.45, 3.52)*1.14 (0.39, 3.33)
 Model 30.97 (0.62, 1.51)1.001.62 (0.98, 2.69)2.27 (1.46, 3.54)*1.13 (0.39, 3.32)
 Model 40.90 (0.57, 1.42)1.001.55 (0.90, 2.65)2.22 (1.38, 3.57)*1.23 (0.41, 3.71)
 Model 50.90 (0.57, 1.43)1.001.59 (0.92, 2.74)2.29 (1.40, 3.77)*1.27 (0.42, 3.88)
uACR ≥ 30 mg/mmol
 Model 10.79 (0.51, 1.24)1.001.02 (0.61, 1.69)1.68 (1.06, 2.64)*(0.59 (0.20, 1.71)
 Model 20.76 (0.48, 1.20)1.000.95 (0.56, 1.60)1.58 (0.98, 2.52)0.54 (0.18, 1.59)
 Model 30.76 (0.48, 1.20)1.000.95 (0.56, 1.61)1.58 (0.99, 2.54)0.53 (0.18, 1.58)
 Model 40.72 (0.45, 1.17)1.000.90 (0.52, 1.58)1.65 (0.99, 2.73)0.58 (0.19, 1.75)
 Model 50.73 (0.45, 1.18)1.000.93 (0.53, 1.64)1.74 (1.03, 2.93)*0.61 (0.20, 1.86)
Orm > P75 (Orm = 21.27 mg/L)
 Model 11.28 (0.93, 2.25)1.001.79 (1.18, 2.73)*1.63 (1.07, 2.49)*3.63 (2.17, 6.08)*
 Model 21.31 (0.94, 1.83)1.001.94 (1.25, 3.01)*1.76 (1.14, 2.73)*3.02 (1.53, 5.95)*
 Model 31.31 (0.94, 1.83)1.001.94 (1.25, 3.02)*1.76 (1.14, 2.73)*3.05 (1.54, 6.01)*
 Model 41.29 (0.92, 1.82)1.001.97 (1.25, 3.10)*1.61 (1.02, 2.54)*3.13 (1.56, 6.27)*
 Model 51.27 (0.90, 1.80)1.001.92 (1.21, 3.05)*1.53 (0.95, 2.46)2.92 (1.44, 5.94)*
α 1MG > P75 (α 1MG = 29.75 mg/L)
Model 11.40 (1.02, 1.93)*1.001.64 (1.07, 2.51)*1.45 (0.94, 2.23)3.02 (1.57, 5.97)*
 Model 21.33 (0.95, 1.85)1.001.56 (0.99, 2.44)1.40 (0.89, 2.20)2.95 (1.48, 5.84)*
 Model 31.33 (0.95, 1.85)1.001.56 (0.99, 2.44)1.39 (0.89, 2.19)2.92 (1.47, 5.79)*
 Model 41.31 (0.93, 1.85)1.001.52 (0.96, 2.43)1.31 (0.83, 2.09)2.96 (1.47, 5.95)*
 Model 51.31 (0.92, 1.85)1.001.53 (0.96, 2.45)1.31 (0.81, 2.13)2.91 (1.43, 5.94)*
TRF > P75 (TRF = 3.83 mg/L)
 Model 11.39 (0.99, 1.95)1.002.28 (1.49, 3.50)*2.61 (1.72, 3.97)*4.56 (2.37, 8.75)*
 Model 21.43 (1.02, 2.02)*1.002.46 (1.58, 3.84)*2.80 (1.82, 4.32)*5.04 (2.58, 9.86)*
 Model 31.44 (1.02, 2.02)*1.002.47 (1.58, 3.86)*2.80 (1.81, 4.32)*5.09 (2.60, 9.96)*
 Model 41.34 (0.94, 1.91)1.002.48 (1.57, 3.93)*2.50 (1.60, 3.92)*5.28 (2.65, 10.55)*
 Model 51.33 (0.93, 1.89)1.002.46 (1.54, 3.92)*2.42 (1.51, 3.87)*5.08 (2.51, 10.27)*
  1. Group 1: moderate-stable group; group 2: low-stable group; group 3: moderate-increasing group; group 4: moderate-decreasing group; group 5: high-stable group
  2. Model 1: no adjustment;
  3. Model 2: adjusted for age, gender;
  4. Model 3: further adjusted for history of myocardial infarction, stroke, cancer;
  5. Model 4: further adjusted for education, physics, smoking status, drinking status, salt habit, triglyceride, total cholesterol, body mass index, LDL, HDL, hsCRP;
  6. Model 5: further adjusted for antihypertensive, hypoglycemic, lipid-lowering drug;
  7. eGFR estimated glomerular filtration rate, α1MG Urinary α1-microglobulin, TRF Transferrinuria, Orm Urinary α1-acid glycoprotein, uACR urinary albumin creatinine ratio